IGF2R
Basic information
Region (hg38): 6:159969082-160113507
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the IGF2R gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 13 | 19 | ||||
missense | 104 | 12 | 126 | |||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | 2 | |||
non coding | 0 | |||||
Total | 0 | 2 | 105 | 25 | 14 |
Variants in IGF2R
This is a list of pathogenic ClinVar variants found in the IGF2R region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
6-159969289-CCCGCCCG-C | Hepatocellular carcinoma | Likely pathogenic (May 03, 2020) | ||
6-159969296-G-C | Hepatocellular carcinoma | Uncertain significance (Mar 09, 2021) | ||
6-159969298-C-T | not specified | Uncertain significance (Dec 20, 2023) | ||
6-159969361-C-G | not specified | Uncertain significance (Dec 26, 2023) | ||
6-159991230-A-G | not specified | Uncertain significance (Mar 14, 2023) | ||
6-159991243-G-A | not specified | Uncertain significance (Dec 22, 2023) | ||
6-159991254-A-G | not specified | Likely benign (Oct 05, 2022) | ||
6-159991281-G-A | not specified | Uncertain significance (Jun 27, 2022) | ||
6-160009030-G-A | not specified | Uncertain significance (Jan 06, 2023) | ||
6-160009072-G-A | not specified | Uncertain significance (Feb 06, 2023) | ||
6-160009093-A-G | not specified | Uncertain significance (Jan 17, 2024) | ||
6-160009133-T-A | Hepatocellular carcinoma | Pathogenic (Jun 15, 2021) | ||
6-160010723-C-T | Premature ovarian failure | Likely pathogenic (Mar 02, 2020) | ||
6-160010747-G-A | not specified | Uncertain significance (May 11, 2022) | ||
6-160010748-C-A | not specified | Uncertain significance (Aug 08, 2022) | ||
6-160024661-C-T | Likely benign (Jun 01, 2022) | |||
6-160024662-G-C | not specified | Uncertain significance (Sep 17, 2021) | ||
6-160024672-C-T | not specified | Uncertain significance (Oct 18, 2021) | ||
6-160024689-G-C | not specified | Uncertain significance (Apr 24, 2024) | ||
6-160027224-C-G | not specified | Uncertain significance (Aug 12, 2021) | ||
6-160027232-A-G | Benign (Jul 23, 2018) | |||
6-160027261-G-T | not specified | Uncertain significance (Aug 17, 2022) | ||
6-160027264-G-A | Likely benign (Feb 01, 2023) | |||
6-160027283-C-T | Benign (Dec 31, 2019) | |||
6-160027304-C-T | not specified | Uncertain significance (May 24, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
IGF2R | protein_coding | protein_coding | ENST00000356956 | 48 | 144409 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 8.50e-8 | 125717 | 0 | 31 | 125748 | 0.000123 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.07 | 1203 | 1.42e+3 | 0.846 | 0.0000835 | 16329 |
Missense in Polyphen | 347 | 503.96 | 0.68855 | 5625 | ||
Synonymous | -1.33 | 647 | 605 | 1.07 | 0.0000432 | 4796 |
Loss of Function | 8.71 | 17 | 120 | 0.142 | 0.00000592 | 1464 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000232 | 0.000232 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000163 | 0.000163 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.000132 | 0.000132 |
Middle Eastern | 0.000163 | 0.000163 |
South Asian | 0.0000980 | 0.0000980 |
Other | 0.000164 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6- phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex. This receptor also binds IGF2. Acts as a positive regulator of T-cell coactivation, by binding DPP4. {ECO:0000269|PubMed:10900005}.;
- Pathway
- Endocytosis - Homo sapiens (human);Lysosome - Homo sapiens (human);IGF-Ncore;miR-targeted genes in adipocytes - TarBase;miR-targeted genes in epithelium - TarBase;miR-targeted genes in leukocytes - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Golgi Associated Vesicle Biogenesis;Clathrin derived vesicle budding;Neutrophil degranulation;trans-Golgi Network Vesicle Budding;Vesicle-mediated transport;Membrane Trafficking;Innate Immune System;Immune System;Clathrin-mediated endocytosis;Cargo recognition for clathrin-mediated endocytosis;Retrograde transport at the Trans-Golgi-Network;Intra-Golgi and retrograde Golgi-to-ER traffic
(Consensus)
Recessive Scores
- pRec
- 0.705
Intolerance Scores
- loftool
- 0.339
- rvis_EVS
- -1.93
- rvis_percentile_EVS
- 1.9
Haploinsufficiency Scores
- pHI
- 0.145
- hipred
- Y
- hipred_score
- 0.747
- ghis
- 0.448
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.977
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | High |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Igf2r
- Phenotype
- limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; respiratory system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype;
Gene ontology
- Biological process
- liver development;post-Golgi vesicle-mediated transport;receptor-mediated endocytosis;lysosomal transport;signal transduction;G protein-coupled receptor signaling pathway;spermatogenesis;post-embryonic development;animal organ regeneration;response to retinoic acid;positive regulation of apoptotic process;neutrophil degranulation;insulin-like growth factor receptor signaling pathway;membrane organization
- Cellular component
- nuclear envelope lumen;lysosomal membrane;endosome;early endosome;late endosome;Golgi apparatus;trans-Golgi network;plasma membrane;integral component of plasma membrane;focal adhesion;cell surface;membrane;clathrin coat;transport vesicle;clathrin-coated vesicle;endocytic vesicle;trans-Golgi network transport vesicle;clathrin-coated vesicle membrane;secretory granule membrane;trans-Golgi network membrane;perinuclear region of cytoplasm;extracellular exosome
- Molecular function
- G-protein alpha-subunit binding;retinoic acid binding;insulin-like growth factor-activated receptor activity;protein binding;insulin-like growth factor binding;mannose binding;enzyme binding;insulin-like growth factor II binding;kringle domain binding;signaling receptor activity;identical protein binding;phosphoprotein binding